Rib-X Pharmaceuticals, Inc. Presents Data from Multiple Radezolid Studies at ICAAC Including Successful Intravenous Dosing in Phase 1 and Favorable Long-Term Safety and Tolerability Vs. Linezolid in Vivo
9/12/2012 10:34:58 AM
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc. announced today that the Company’s next-generation oxazolidinone, radezolid, was featured in one oral and three poster presentations at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 9-12, 2012 in San Francisco, CA. New data presented by Rib-X included the results from a positive Phase 1 intravenous (IV) dosing study conducted in healthy subjects and an in vivo long-term safety study versus linezolid. Third-party presentations highlighted radezolid as a promising next-generation oxazolidinone with a favorable long-term safety profile, IV and oral dosing potential, and potent activity against multiple linezolid-resistant Gram-positive strains.